Molecular profiling of clear-cell renal cell carcinoma and prediction of response to targeted therapies against the vascular endothelial growth factor receptor, immune checkpoint inhibitors and mTOR inhibitors in the metastatic setting.
RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORTARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORS
Targeting deubiquitinases in hepatocellular carcinoma: a preclinical assessment of the therapeutic potential in combinatory treatments with tyrosine kinase inhibitors and immune checkpoint inhibition.
Immune Checkpoint Inhibitors induce endothelial inflammation as first step in cardiovascular side effects
Response prediction in metastatic clear-cell renal cell carcinoma treated with angiogenesis and/or immune checkpoint inhibitors
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
Health-related quality of life, psychological outcome and neurocognitive function in metastatic melanoma survivors treated with immune checkpoint inhibitors
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?